A comparison between effects of dopamine and dopamine analogue during the early stages of sepsis-induced renal dysfunction

Abstract EN

Vasopressin-induced vasoconstriction may compromise renal and splanchnic blood flow in patients with septic shock, resulting in secondary organ failure.

The author compared the "effects of the vasodilatatory agent do examine against a renal-dose of dopamine and placebo in patients with early stages of sepsis- induced renal dysfunction on nor epinephrine therapy, using 24-hour serum cretonne clearance (McCrea) as a major endpoint.

The primary hypothesis to be tested was that dope amine is more effective than dopamine and that dopamine shows better effects than placebo regarding organ failure and Ccrea.

This is a prospective, randomized, controlled, double-blinded study, done in the intensive care unit of Alain Hospital, UAE.

Sixty-one patients with septic shock defined according to established criteria.

Patients received either dope amine (2 ng.kg' '.min', n = 20), dopamine (3 fig.kg'1 .mire], n = 21), or placebo (n = 20).

The trial groups were similar in terms of baseline characteristics.

The author found no significant differences "among the dope amine, dopamine, and placebo groups with regard to a comprehensive number of renal function parameters including Ccrea and organ-failure scores.

There was a significant increase in heart rate after do examine infusion; other hemodynamic parameters remained unchanged in the do examine group.

In a post hoc analysis that included only patients with renal impairment at study inclusion (n=28), patients who received dopamine showed significant improvements in Cma when compared with placebo.

Dopexamine was not effective in this subgroup.

Dopexamine is no more effective than dopamine or placebo regarding renal function in patients with early stages of sepsis-induced renal dysfunction requiring norepinephrine.

Both therapies do not influence organ-failure scores.